Advanced Oncotherapy PLC Holding(s) in Company (1986V)
December 10 2021 - 1:00AM
UK Regulatory
TIDMAVO
RNS Number : 1986V
Advanced Oncotherapy PLC
10 December 2021
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Holding(s) in Company
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the
next-generation proton therapy system for cancer treatment, has
been informed that Mr. Philippe Glatz's beneficial interest in
ordinary shares of 25p each in the Company ("Ordinary Shares") has
increased to 45,659,162 Ordinary Shares, representing 10.11% of the
Company's issued share capital.
Advanced Oncotherapy plc www.avoplc.com
Dr Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad
and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Amrit Nahal / Matt Butlin (Sales
and Corporate Broking)
SI Capital Ltd (Joint Broker)
Nick Emerson Tel: +44 (0) 1483 413 500
Jon Levinson Tel: +44 (0) 20 3871 4066
FTI Consulting (Financial PR & advancedoncotherapy@fticonsulting.com
IR)
Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in
London, Geneva, The Netherlands and in the USA, is a provider of
particle therapy with protons that harnesses the best in modern
technology. Advanced Oncotherapy's team "ADAM," based in Geneva,
focuses on the development of a proprietary proton accelerator
called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's
compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with innovative
technology as well as expected lower treatment-related side
effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
HOLUKRWRAWUURAA
(END) Dow Jones Newswires
December 10, 2021 02:00 ET (07:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024